Vaccination with leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis

Science Translational Medicine

Volumn 5, Issue 202, 2013, Pages

  Guha, Rajan ^a   Gupta, Deepika ^b   Rastogi, Ruchir ^b   Vikram, Rajagopal ^b   Krishnamurthy, Ganga ^b   Bimal, Sanjiva ^c   Roy, Syamal ^a   Mukhopadhyay, Amitabha ^b  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^c RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HBR DNA VACCINE; HEMOGLOBIN RECEPTOR ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA VACCINE; PARASITE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DNA IMMUNIZATION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; EXPRESSION VECTOR; FLOW CYTOMETRY; HAMSTER; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; VISCERAL LEISHMANIASIS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CONSERVED SEQUENCE; CRICETINAE; DNA; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE; TH1 CELLS; VACCINATION;

EID: 84884683266     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006406     Document Type: Article

References (57)

1. L. Kedzierski, A. Sakthianandeswaren, J. M. Curtis, P. C. Andrews, P. C. Junk, K. L. Kedzierska, Leishmaniasis: Current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 16, 599-614 (2009).
2. L. I. McCall, W. W. Zhang, G. Matlashewski, Determinants for the development of visceral leishmaniasis disease. PLoS Pathog. 9, e1003053 (2013).
3. P. Kaye, P. Scott, Leishmaniasis: Complexity at the host-pathogen interface. Nat. Rev. Microbiol. 9, 604-615 (2011).
4. S. L. Croft, G. H. Coombs, Leishmaniasis - Current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19, 502-508 (2003).
5. B. Singh, S. Sundar, Leishmaniasis: Vaccine candidates and perspectives. Vaccine 30, 3834-3842 (2012).
6. K. J. Evans, L. Kedzierski, Development of vaccines against visceral leishmaniasis. J. Trop. Med. 2012, 892817 (2012).
7. E. M. Carvalho, R. Badaró, S. G. Reed, T. C. Jones, W. D. Johnson Jr., Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76, 2066-2069 (1985).
8. O. Bacellar, A. D'Oliveira Jr., S. Jerônimo, E. M. Carvalho, IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12, 1228-1231 (2000).
9. S. Gurunathan, C. Prussin, D. L. Sacks, R. A. Seder, Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4, 1409-1415 (1998).
10. J. F. Sah, H. Ito, B. K. Kolli, D. A. Peterson, S. Sassa, K. P. Chang, Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J. Biol. Chem. 277, 14902 -14909 (2002).
11. J. X. Kelly, M. V. Ignatushchenko, H. G. Bouwer, D. H. Peyton, D. J. Hinrichs, R. W. Winter, M. Riscoe, Antileishmanial drug development: Exploitation of parasite heme dependency. Mol. Biochem. Parasitol. 126, 43-49 (2003).
12. S. Sengupta, J. Tripathi, R. Tandon, M. Raje, R. P. Roy, S. K. Basu, A. Mukhopadhyay, Hemoglobin endocytosis in Leishmania is mediated through a 46-kDa protein located in the flagellar pocket. J. Biol. Chem. 274, 2758-2765 (1999).
13. S. B. Singh, R. Tandon, G. Krishnamurthy, R. Vikram, N. Sharma, S. K. Basu, A. Mukhopadhyay, Rab5-mediated endosome-endosome fusion regulates hemoglobin endocytosis in Leishmania donovani. EMBO J. 22, 5712-5722 (2003).
14. N. Patel, S. B. Singh, S. K. Basu, A. Mukhopadhyay, Leishmania requires Rab7-mediated degradation of endocytosed hemoglobin for their growth. Proc. Natl. Acad. Sci. U.S.A. 105, 3980- 3985 (2008).
15. S. Agarwal, R. Rastogi, D. Gupta, N. Patel, M. Raje, A. Mukhopadhyay, Clathrin-mediated hemoglobin endocytosis is essential for survival of Leishmania. Biochim. Biophys. Acta 1833, 1065-1077 (2013).
16. G. Krishnamurthy, R. Vikram, S. B. Singh, N. Patel, S. Agarwal, G. Mukhopadhyay, S. K. Basu, A. Mukhopadhyay, Hemoglobin receptor in Leishmania is a hexokinase located in the flagellar pocket. J. Biol. Chem. 280, 5884-5891 (2005).
17. F. R. Opperdoes, Compartmentation of carbohydrate metabolism in trypanosomes. Annu. Rev. Microbiol. 41, 127-151 (1987).
18. P. M. Kaye, M. Svensson, M. Ato, A. Maroof, R. Polley, S. Stager, S. Zubairi, C. R. Engwerda, The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 201, 239-253 (2004).
19. S. Stäger, D. F. Smith, P. M. Kaye, Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165, 7064-7071 (2000).
20. A. Ghosh, W. W. Zhang, G. Matlashewski, Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20, 59-66 (2001).
21. R. Basu, S. Bhaumik, J. M. Basu, K. Naskar, T. De, S. Roy, Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: Evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174, 7160-7171 (2005).
22. S. Rafati, F. Zahedifard, F. Nazgouee, Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24, 2169-2175 (2006).
23. P. K. Kushawaha, R. Gupta, S. Sundar, A. A. Sahasrabuddhe, A. Dube, Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J. Immunol. 187, 6417-6427 (2011).
24. Y. Wang, Y. Chen, L. Xin, S. M. Beverley, E. D. Carlsen, V. Popov, K. P. Chang, M. Wang, L. Soong, Differential microbicidal effects of human histone proteins H2A and H2B on Leishmania promastigotes and amastigotes. Infect. Immun. 79, 1124-1133 (2011).
25. P. K. Kushawaha, R. Gupta, C. D. Tripathi, P. Khare, A. K. Jaiswal, S. Sundar, A. Dube, Leishmania donovani triose phosphate isomerase: A potential vaccine target against visceral leishmaniasis. PLoS One 7, e45766 (2012).
26. B. Sukumaran, P. Tewary, S. Saxena, R. Madhubala, Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21, 1292-1299 (2003).
27. S. Gurunathan, D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, R. A. Seder, Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186, 1137-1147 (1997).
28. P. C. Melby, J. Yang, W. Zhao, L. E. Perez, J. Cheng, Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69, 4719-4725 (2001).
29. S. Bhaumik, R. Basu, S. Sen, K. Naskar, S. Roy, KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27, 1306-1316 (2009).
30. Y. Goto, A. Bhatia, V. S. Raman, H. Liang, R. Mohamath, A. F. Picone, S. E. Vidal, T. S. Vedvick, R. F. Howard, S. G. Reed, KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin. Vaccine Immunol. 18, 1118-1124 (2011).
31. R. N. Coler, Y. A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, S. G. Reed, Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70, 4215-4225 (2002).
32. L. Gradoni, V. Foglia Manzillo, A. Pagano, D. Piantedosi, R. De Luna, M. Gramiccia, A. Scalone, T. Di Muccio, G. Oliva, Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23, 5245-5251 (2005).
33. J. Chakravarty, S. Kumar, S. Trivedi, V. K. Rai, A. Singh, J. A. Ashman, E. M. Laughlin, R. N. Coler, S. J. Kahn, A. M. Beckmann, K. D. Cowgill, S. G. Reed, S. Sundar, F. M. Piazza, A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29, 3531-3537 (2011).
34. N. Dunning, Leishmania vaccines: From leishmanization to the era of DNA technology. Biohorizons 2, 73-82 (2009).
35. N. E. Reiner, J. H. Finke, Interleukin 2 deficiency in murine Leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. J. Immunol. 131, 1487-1491 (1983).
36. + T cell numbers. J. Immunol. 169, 4850-4860 (2002).
37. C. M. Snapper, W. E. Paul, Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236, 944-947 (1987).
38. A. J. Gerth, L. Lin, S. L. Peng, T-bet regulates T-independent IgG2a class switching. Int. Immunol. 15, 937-944 (2003).
39. R. A. Seder, A. V. Hill, Vaccines against intracellular infections requiring cellular immunity. Nature 406, 793-798 (2000).
40. A. G. Goodman, P. P. Heinen, S. Guerra, A. Vijayan, C. O. Sorzano, C. E. Gomez, M. Esteban, A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS One 6, e25938 (2011).
41. H1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843-850 (2007).
42. H. W. Murray, C. F. Nathan, Macrophage microbicidal mechanisms in vivo: Reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189, 741-746 (1999).
43. A. M. Cooper, D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, I. M. Orme, Disseminated tuberculosis in interferon γ gene-disrupted mice. J. Exp. Med. 178, 2243-2247 (1993).
44. F. Y. Liew, Y. Li, S. Millott, Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145, 4306-4310 (1990).
45. H1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3, 852-858 (2002).
46. F. P. Heinzel, D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, M. K. Gately, Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177, 1505-1509 (1993).
47. + T-cell responses. Nat. Med. 9, 1287-1292 (2003).
48. R. Basu, S. Roy, P. Walden, HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J. Infect. Dis. 195, 1373-1380 (2007).
49. F. Benjelloun, P. Lawrence, B. Verrier, C. Genin, S. Paul, Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J. Virol. 86, 13152-13163 (2012).
50. S. Zakeri, L. Babaeekhou, A. A. Mehrizi, M. Abbasi, N. D. Djadid, Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission. Am. J. Trop. Med. Hyg. 84, 944-950 (2011).
51. M. Forgber, R. Basu, K. Roychoudhury, S. Theinert, S. Roy, S. Sundar, P. Walden, Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS One 1, e40 (2006).
52. C. Zaph, J. Uzonna, S. M. Beverley, P. Scott, Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat. Med. 10, 1104-1110 (2004).
53. S. Carvalho, T. Cruz, N. Santarém, H. Castro, V. Costa, A. M. Tomás, Heme as a source of iron to Leishmania infantum amastigotes. Acta Trop. 109, 131-135 (2009).
54. A. K. Haldar, S. Banerjee, K. Naskar, D. Kalita, N. S. Islam, S. Roy, Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-γ to IL-10 ratio. Exp. Parasitol. 122, 145-154 (2009).
55. A. Mukhopadhyay, G. Chaudhuri, S. K. Arora, S. Sehgal, S. K. Basu, Receptor-mediated drug delivery to macrophages in chemotherapy of leishmaniasis. Science 244, 705-707 (1989).
56. I. Ramos, A. Alonso, J. M. Marcen, A. Peris, J. A. Castillo, M. Colmenares, V. Larraga, Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26, 333-344 (2008).
57. R. Guha, S. Das, J. Ghosh, K. Naskar, A. Mandala, S. Sundar, J. C. Dujardin, S. Roy, Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. Vaccine 31, 1905-1915 (2013).